Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDActual EPS
NeuroSense Therapeutics Ltd. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 04/07/2025 | Q4 2024 | N/A | -$0.09 | N/A | N/A | $0 |
| 09/30/2024 | Q3 2024 | N/A | -$0.11 | N/A | N/A | $0 |
| 09/30/2024 | Q2 2024 | N/A | -$0.05 | N/A | N/A | $0 |
| 03/30/2024 | Q1 2024 | N/A | -$0.35 | N/A | N/A | $0 |
| 04/04/2024 | Q4 2023 | N/A | -$0.19 | N/A | N/A | $0 |
| 09/29/2023 | Q3 2023 | N/A | $0.06 | N/A | N/A | $0 |
| 06/30/2023 | Q2 2023 | N/A | -$0.38 | N/A | N/A | $0 |
| 04/17/2023 | Q1 2023 | N/A | -$0.32 | N/A | N/A | $0 |
| 03/22/2023 | Q4 2022 | N/A | -$0.25 | N/A | N/A | $0 |
| 09/30/2022 | Q3 2022 | N/A | -$0.23 | N/A | N/A | $0 |
| 01/19/2023 | Q2 2022 | N/A | -$0.30 | N/A | N/A | $0 |
| 03/31/2022 | Q1 2022 | N/A | -$0.19 | N/A | N/A | $0 |
| 04/14/2022 | Q4 2021 | N/A | -$0.01 | N/A | N/A | $0 |
| 09/30/2021 | Q3 2021 | N/A | -$0.08 | N/A | N/A | $0 |
| 06/30/2021 | Q2 2021 | N/A | -$0.08 | N/A | N/A | $0 |
| 03/31/2021 | Q1 2021 | N/A | -$0.19 | N/A | N/A | $0 |
| 12/31/2020 | Q4 2020 | N/A | -$0.20 | N/A | N/A | $0 |
| 09/29/2020 | Q3 2020 | N/A | -$0.20 | N/A | N/A | $0 |
| 06/29/2020 | Q2 2020 | N/A | -$0.06 | N/A | N/A | $0 |
| 03/30/2020 | Q1 2020 | N/A | -$0.06 | N/A | N/A | $0 |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
NeuroSense Therapeutics Ltd. Earnings: FAQ's
The conference call for NeuroSense Therapeutics Ltd.'s latest earnings report can be listened to online.
The conference call transcript for NeuroSense Therapeutics Ltd.'s latest earnings report can be read online.
NeuroSense Therapeutics Ltd. (:NRSNW) has a recorded net income of $-10,210,000.NeuroSense Therapeutics Ltd. has generated $-0.55 earnings per share over the last four quarters.
NeuroSense Therapeutics Ltd. (:NRSNW) has a price-to-earnings ratio of -3.5 and price/earnings-to-growth ratio is -0.25.